Capmatinib xHCl 是一种有效的、口服活性的、选择性的和 ATP 竞争性 c-Met 激酶抑制剂，有效地阻断体外激酶活性 (IC50 = 0.13 nM) 以及在细胞中的组成型或 HGF 刺激活性（IC50 值范围从 0.3 到1.1纳米）。

Capmatinib xHCl is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50 = 0.13 nM) as well as constitutive or HGF-stimulated activity in cells (IC50 values range from 0.3 to 1.1 nM).

Capmatinib hydrochloride blocks cell proliferation and migration or induces apoptosis in different types of cancer cells[1]

1029714-89-3

C23H18ClFN6O

448.89

INC280;Capmatinib hydrochloride(free base);INCB28060

DMSO:10 mM
Powder: -20°C for 3 years
In solvent: -80°C for 2 years